NovaBay Pharma (NBY) Announces Board Changes

January 28, 2022 6:51 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces the appointments of Audrey Kunin, M.D. and Julie Garlikov to the NovaBay Board of Directors. Dr. Kunin is a recognized leader in the skincare product industry and has served as NovaBay’s Chief Product Officer since its acquisition in November 2021 of DERMAdoctor, LLC, a company she cofounded. Ms. Garlikov brings to NovaBay more than 25 years of marketing experience, including deep expertise in health, beauty, eyecare and dermatology products.

NovaBay also announces the resignation of Zhang Xinzhou (Paul) Li as a director. His vacancy is being filled by Yongxiang (Sean) Zheng. All changes to the Board of Directors are effective immediately and result in an increase to the size of NovaBay’s Board from six to eight members.

“This is an exciting, transformational time at NovaBay with the recent addition of DERMAdoctor and our planned further expansion into the large, lucrative OTC eyecare and skincare markets. We are delighted to welcome professionals to our Board who bring highly relevant experience and records of success,” said Paul E. Freiman, Board Chairman. “In less than two months Audrey has proven her leadership skills and industry knowledge, and is instrumental to our new product strategy and the development of innovative products for both the skincare and eyecare markets. We look forward to calling upon Julie’s expertise and fresh ideas, particularly in formulating effective digital and social media strategies to create brand awareness and demand generation for our products.

“Sean has international experience in the medical device arena and was recommended to fill our Board vacancy by several of our large ex-US stockholders,” he added. “The Board would like to thank Paul for his valuable contributions over his nearly seven years of service as a director.”

“We have created a new NovaBay with the acquisition of DERMAdoctor with revenues diversified across the eyecare and skincare markets and a path toward profitability,” said Justin Hall, NovaBay CEO. “With the addition of our new directors, our Board better reflects our new direction with added industry and marketing expertise that we expect will be highly valuable to our success.”

Dr. Kunin has been the creative force behind all DERMAdoctor products since 1998. At DERMAdoctor, she led the formulation and development of numerous innovative skincare products. Dr. Kunin graduated from Ohio State University and received her M.D. from the Medical College of Ohio. She completed postgraduate training in dermatology at the Medical College of Virginia after serving as Chief Resident. She is a fellow of the American Academy of Dermatology and formerly served as an Assistant Clinical Instructor of Dermatology at the University of Kansas School of Medicine.

Ms. Garlikov is a classically trained consumer product goods marketer who gained her consumer experience at Procter & Gamble, Johnson & Johnson and PepsiCo. Since 2020 she has served as Vice President of Marketing of GRAIL, LLC, a multi-cancer early detection company. Prior to GRAIL she was Chief Marketing Officer at NewAge, Inc., a healthy products company where she led all aspects of global marketing including product development, creative, social media, digital and branding. She previously was Chief Marketing Officer of Shaklee Corporation and held senior marketing positions at dermatological skincare companies Rodan + Fields, Obagi Medical and Nuvesse Skin Therapies. Ms. Garlikov holds a BA from the University of California, Berkeley and an MBA from Columbia University.

Mr. Zheng brings to NovaBay more than 27 years of experience in mergers and acquisitions, fund management and the import/export business. He is CEO of Q3 Medical Devices (Shanghai) Co. Ltd., having previously held CEO and Managing Director positions at Boill Fund Management (HK) Co., Ltd. and Sprott-Zijin Mining Fund, a joint venture fund between Zijin Mining Group and Sprott Asset Management LP. Mr. Zheng is a chartered financial analyst and graduated from China’s Renmin University . He received an MBA from the University of New South Wales in 2002, and an MA of EMBA from China Europe International Business School in 2010.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Board Changes, Corporate News

Related Entities

Twitter, S1, Earnings, Definitive Agreement